{"id":78,"date":"2026-02-01T22:43:40","date_gmt":"2026-02-01T22:43:40","guid":{"rendered":"http:\/\/192.168.0.101\/blog\/?p=78"},"modified":"2026-02-04T00:35:25","modified_gmt":"2026-02-04T00:35:25","slug":"medtrac-internal-discovery-notice","status":"publish","type":"post","link":"http:\/\/netlite.community\/blog\/index.php\/2026\/02\/01\/medtrac-internal-discovery-notice\/","title":{"rendered":"MEDTRAC\u2122 \u2013 Remote SCAN"},"content":{"rendered":"\n


Not for External Distribution<\/strong><\/h2>\n\n\n\n

Extremely Private & Confidential \u2013 Internal Circulation Only<\/strong><\/p>\n\n\n\n

Summary<\/strong><\/h3>\n\n\n\n

MEDTRAC\u2122 has identified a novel remote biofeedback-based monitoring method<\/strong> that materially extends the company\u2019s existing testing capabilities. Initial internal testing conducted today produced highly concordant results<\/strong>, warranting controlled clinic validation before any external communication. The R-SCAN can be paired with HRV wearable devices (for greater correlation) or used remotely on its own. <\/p>\n\n\n\n

The Key aspect of this discovery is that it can be conducted remotely and possibly without DNA.<\/p>\n\n\n\n

This notice documents the discovery for internal awareness only.<\/p>\n\n\n\n

Mockup Images provide an illustration.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n\n\n\n

INTERNAL PRESS RELEASE \u2013 ON HOLD<\/strong><\/h2>\n\n\n\n

(Draft for internal review \u2013 not approved for publication)<\/em><\/p>\n\n\n\n

MEDTRAC\u2122 Identifies Novel Remote Biofeedback Method for Continuous Health State Monitoring<\/strong><\/h3>\n\n\n\n

Malta \u2013 1 February 2026<\/strong><\/p>\n\n\n\n

MEDTRAC\u2122 today confirmed the internal identification of a previously unrecognised remote biofeedback data acquisition and analysis method<\/strong> that removes the need for any weaable on adhacent device, representing one of the most strategically significant technical discoveries in the company\u2019s history.<\/p>\n\n\n\n

The method enables remote capture and interpretation of regulatory biofeedback signals<\/strong>, which\u2014when combined with MEDTRAC\u2019s established local Grade Scan methodology<\/strong>\u2014creates a multi-layered, longitudinal view of system load, regulatory balance, and health-state dynamics<\/strong>.<\/p>\n\n\n\n

This combined model moves MEDTRAC beyond static, point-in-time assessments toward continuous or near-continuous system state monitoring<\/strong>, with data refresh cycles configurable from hourly to daily. We will carry out further inteneeal testing to validate this finding. <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

A New Class of Remote Screening & Monitoring Capability<\/strong><\/h4>\n\n\n\n

Unlike conventional remote health tools that rely primarily on questionnaires or limited biometric proxies, this approach captures complex response-pattern data<\/strong> remotely without any device, enabling:<\/p>\n\n\n\n

    \n
  • Continuous tracking of stress, recovery, and regulatory load<\/li>\n\n\n\n
  • Longitudinal assessment of pathogen and system burden trends<\/li>\n\n\n\n
  • High-resolution visualisation of health-state trajectories<\/li>\n\n\n\n
  • Objective monitoring of change during recovery or intervention phases<\/li>\n<\/ul>\n\n\n\n

    When paired with locally performed Grade Scans<\/strong> (clinic or supervised home use), the system forms an alternative to our existing complementary testing tools and strethens the remote only service. This <\/strong>bridges in-person precision with remote scalability<\/strong>.<\/p>\n\n\n\n

    \n\n\n\n

    Ultra-Low-Cost, High-Scalability Architecture<\/strong><\/h4>\n\n\n\n

    A core strength of the discovery is its exceptionally low projected hardware cost<\/strong>, with anticipated public unit costs below USD $100 at scale<\/strong>.<\/p>\n\n\n\n

    This enables:<\/p>\n\n\n\n

      \n
    • Affordable, ongoing monitoring for individuals<\/li>\n\n\n\n
    • Population-scale research and cohort deployment<\/li>\n\n\n\n
    • Reduced dependency on repeated clinic visits<\/li>\n\n\n\n
    • Accessibility in low-resource and geographically distributed settings<\/li>\n<\/ul>\n\n\n\n

      The architecture supports monitoring and feedback intelligence<\/strong>, with therapeutic use cases treated as a separate downstream application layer<\/strong>, subject to regulatory and governance controls.<\/p>\n\n\n\n

      <\/div>\n\n\n\n

      Early Validation & Development Path<\/strong><\/h2>\n\n\n\n
        \n
      • Initial proof-of-concept testing completed using AI-assisted analysis<\/strong> without dedicated software automation whihc will be needed for testing, as its too timeconsuming to be done manually. <\/li>\n\n\n\n
      • Early results have exceeded internal expectations<\/li>\n\n\n\n
      • No public claims or external validation asserted at this stage<\/li>\n<\/ul>\n\n\n\n

        Next phase:<\/p>\n\n\n\n

          \n
        • Controlled clinic validation<\/li>\n\n\n\n
        • Expanded AI-assisted analysis of data provided<\/li>\n\n\n\n
        • Automated proof-of-concept software development<\/li>\n\n\n\n
        • Research-grade visualisation and dashboards to be develoepd<\/li>\n\n\n\n
        • Integration into Longevity Trust led and research programmes<\/li>\n\n\n\n
        • Focus on Animal health monitoring to build reliable data<\/li>\n<\/ul>\n\n\n\n
          \n\n\n\n

          Strategic Significance<\/strong><\/h2>\n\n\n\n

          This discovery could be a cornerstone in MEDTRAC\u2019s transition<\/strong> from a clinic-centric model to a platform-led, clinic-enabled ecosystem<\/strong>, where:<\/p>\n\n\n\n

            \n
          • Clients may engage remotely or via partner clinics<\/li>\n\n\n\n
          • Clinics retain responsibility for face-to-face care<\/li>\n\n\n\n
          • MEDTRAC\u2122 provides clinical intelligence, monitoring, and analytics<\/li>\n\n\n\n
          • Foundations and research partners support development and deployment<\/li>\n<\/ul>\n\n\n\n

            Global scale is achieved without compromising clinical integrity or governance<\/strong>.<\/p>\n\n\n\n

            \n\n\n\n

            About MEDTRAC\u2122<\/strong><\/h2>\n\n\n\n

            MEDTRAC\u2122 develops advanced health intelligence systems combining biofeedback, systems analysis, and AI-driven visualisation to support clinicians, researchers, and structured health programmes.<\/p>\n\n\n\n

            \n\n\n\n

            IMPORTANT NOTICE<\/strong><\/h3>\n\n\n\n

            This document is strictly internal<\/strong>. It must not be shared externally or referenced publicly without written approval from Aurvantis Group Directors<\/strong> and review by legal and regulatory counsel.<\/p>\n\n\n\n

            MEDTRAC is part of the Aurvantis Group<\/p>\n\n\n\n

            \"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

            Not for External Distribution Extremely Private & Confidential \u2013 Internal Circulation Only Summary MEDTRAC\u2122 has identified a novel remote biofeedback-based monitoring method that materially extends the company\u2019s existing testing capabilities. Initial internal testing conducted today produced highly concordant results, warranting controlled clinic validation before any external communication. The R-SCAN can be paired with HRV wearable […]<\/p>\n","protected":false},"author":1,"featured_media":71,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-78","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"aioseo_notices":[],"_links":{"self":[{"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/posts\/78","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/comments?post=78"}],"version-history":[{"count":7,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/posts\/78\/revisions"}],"predecessor-version":[{"id":302,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/posts\/78\/revisions\/302"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/media\/71"}],"wp:attachment":[{"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/media?parent=78"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/categories?post=78"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/netlite.community\/blog\/index.php\/wp-json\/wp\/v2\/tags?post=78"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}